I refresher from Dr. Patterson words in a tough da

Quote:

---

Yeah again I think the most compelling data from all the patients, and again being the one seeing the data come off the machines is a unique position, but I think the remarkable aspect of all these patients is this pattern of response. In other words, we’re seeing both a shrinkage of the primary tumor.

We’re seeing shrinkage of any metastatic tumors, and we’re also seeing a dramatic reduction in circulating cells or pieces of cells in the peripheral blood. Now you know we see all the patients have gone down to zero circulating tumor cells, and you have to remember that these are stage four patients and we’ve seen this in both breast cancer and in lung cancer. They could just as easily have their CTC’s go up to 20 or 40. In some of these lung cancer patients that we looked at 80 or above.

So you know it almost looks a little bit mundane over time with these patients because everybody is going to zero, but the impact of that is remarkable and shouldn’t be lost just because you know they all look like they’re behaving the same.

Like I said, I’ve seen CTC’s go the other direction in these end-stage patients and go to levels that we’ve never seen before."

---